Diabetes/Metabolism Research and Reviews最新文献

{"title":"Attenuated Niacin Skin Flushing Response in Diabetic Peripheral Neuropathy Patients: A Novel Clinical Diagnostic Tool","authors":"Tianyuan Jiang,&nbsp;Dandan Wang,&nbsp;Ruoting Chai,&nbsp;Yanyun Hu,&nbsp;Liying Zhu,&nbsp;Fang Fang,&nbsp;Na Li,&nbsp;Chunling Wan,&nbsp;Fang Liu","doi":"10.1002/dmrr.70042","DOIUrl":"https://doi.org/10.1002/dmrr.70042","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The diagnosis of diabetic peripheral neuropathy (DPN) remains challenging because of the lack of objective biomarkers. In this study, we explored the niacin-induced skin flushing response (NSFR) as a novel diagnostic biomarker for DPN on the basis of its association with microangiopathy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We recruited 114 patients with type 2 diabetes (51 with DPN, 59 without DPN, and 4 with unclear neuropathy status) and 91 healthy controls. Peripheral neuropathy was assessed through clinical symptoms and signs, vibration threshold testing and electromyography. NSFR was measured using a six-chamber sandwich patch and six concentrations of aqueous methyl nicotinate. Demographic and clinical data were collected via questionnaires and medical records.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The NSFR was significantly lower in patients with type 2 diabetes than in healthy controls (1613 ± 1130.1 vs. 2494.6 ± 1071.9, <i>p</i> &lt; 0.001) and was further reduced in DPN patients than in those without DPN (1105.4 ± 950.93 vs. 2063.7 ± 1119.3, <i>p</i> &lt; 0.001). The association between the NSFR and the risk of developing DPN remained significant after adjusting for potential confounding factors (OR 0.848, 95% CI 0.757–0.949; <i>p</i> = 0.004). A nomogram illustrated the role of the NSFR in predicting DPN occurrence. The ROC curve for the NSFR had an AUC of 0.740, with 72.55% sensitivity and 66.10% specificity. For the combined model, the AUC improved to 0.898, with 89.58% sensitivity and 78.85% specificity. Decision curve analysis confirmed the practical clinical value of the NSFR for predicting DPN risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>NSFR is significantly associated with the risk of developing peripheral neuropathy in diabetic patients and shows promise as a diagnostic tool for DPN.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 4","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World Study","authors":"Benedetta Maria Bonora,&nbsp;Andrea Giaccari,&nbsp;Agostino Consoli,&nbsp;Fabio Broglio,&nbsp;Angelo Avogaro,&nbsp;Gian Paolo Fadini,&nbsp;for the GLIMPLES Study Investigators","doi":"10.1002/dmrr.70045","DOIUrl":"https://doi.org/10.1002/dmrr.70045","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The introduction of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has provided new avenues for managing type 2 diabetes (T2D), aiming to achieve optimal glycaemic control while minimising treatment burden. We conducted a multicentre retrospective real-world study to assess the effectiveness of semaglutide once-weekly (OW) in patients previously treated with insulin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included individuals with T2D who were on insulin (basal and/or bolus) and initiated OW semaglutide at 18 specialist care centres. We collected retrospective data on baseline clinical characteristics and updated values of HbA1c and body weight. The primary outcome was the change in HbA1c analysed using the mixed model for repeated measures. Secondary outcomes included the changes in body weight, insulin discontinuation and the change in insulin doses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 674 individuals. At baseline, participants were 61.7 years old, with a mean diabetes duration of 11.5 years and an HbA1c of 8.2%. During a median follow-up of 18 months, OW semaglutide initiation led to a significant reduction in HbA1c (−0.9%) and body weight (−4.3 kg), with 60% of patients achieving HbA1c &lt; 7%. 32.8% of patients discontinued insulin therapy, 72.5% of whom achieved an HbA1c &lt; 7%. Among patients on basal-bolus insulin, 75% completely discontinued bolus, 62% of whom achieved an HbA1c &lt; 7%. Predictors of insulin discontinuation included shorter diabetes duration, lower baseline HbA1c, and lower insulin doses. Among patients who remained on insulin, initiation of OW semaglutide was associated with a decrease in total daily insulin requirement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study highlights OW semaglutide as a valuable addition to a T2D regimen based on insulin, offering effective glycaemic and weight control with the potential for insulin deintensification or discontinuation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 4","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70045","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Anti-SARS-CoV-2 IgG Antibody Levels in Vaccinated Diabetes Patients After Recovery From COVID-19","authors":"Xiaoying Zhou,&nbsp;Wenjuan Wang,&nbsp;Yang Yuan,&nbsp;Shanhu Qiu,&nbsp;Yandong Cheng,&nbsp;Zilin Sun","doi":"10.1002/dmrr.70043","DOIUrl":"https://doi.org/10.1002/dmrr.70043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Long-term persistence of anti-SARS-CoV-2 IgG antibodies is critical to protect against SARS-CoV-2 infection or to alleviate the severity of COVID-19. However, the persistence of anti-SARS-CoV-2 IgG after infection in vaccinated diabetes patients is unclear. This study aimed to investigate levels of anti-SARS-CoV-2 IgG 1 year after SARS-CoV-2 infection in diabetes patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study was conducted between December 2023 and January 2024. Participants with SARS-CoV-2 infection during December 2022 to January 2023 were included, and were classified into the diabetes group and non-diabetes group. Anti-N/S IgG antibodies were measured with chemiluminescence immunoassay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 500 participants, 265 diabetes and 235 non-diabetes patients, were included. Anti-N/S IgG levels in the diabetes group were significantly lower than those in the non-diabetes group (1.92 ± 0.58 vs. 2.08 ± 0.42 log₁₀ AU/mL, <i>p</i> = 0.001). In vaccinated subjects, antibody levels in diabetes patients were also lower than those in non-diabetic patients. After adjustment for sex, age, body mass index, estimated glomerular filtration rate, hypertension, and heart disease, diabetes was negatively correlated with antibody titres (<i>β</i> = −0.16, 95% confidence interval (CI) −0.26 to −0.06, <i>p</i> = 0.002). In the diabetes group, after adjustment for confounders, use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) was positively associated with high antibody levels (odds ratio 3.84, 95% CI 1.70–8.65, <i>p</i> = 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vaccinated diabetes patients have lower anti-N/S IgG antibodies than non-diabetic patients 12 months after infection. SGLT-2i is associated with higher anti-N/S IgG antibody levels in diabetes patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 4","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143861898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Now the Time to Review the Diabetes Diagnostic Criteria?","authors":"Maja Cigrovski Berkovic,&nbsp;Felice Strollo,&nbsp;Antonio Ceriello","doi":"10.1002/dmrr.70046","DOIUrl":"https://doi.org/10.1002/dmrr.70046","url":null,"abstract":"<p>The prevention of prediabetes and type 2 diabetes mellitus (T2DM) remains a significant challenge for health systems worldwide. New technology and its expanding spread within the general population can be a helpful tool for healthcare professionals to identify those at risk for diabetes and develop effective and personalized interventions. Recent advancements in continuous glucose monitoring (CGM) technology have provided new insights into interstitial glucose levels, even among healthy individuals. An increasing number of athletes, especially in endurance sports, utilize CGM data during training and competitions to optimize their energy levels. This data-driven approach has led to significant improvements, such as reducing race times by critical seconds—often enough to secure medals. Furthermore, non-athletes are utilizing CGM to make healthier food choices and mitigate postprandial glucose excursions, which can help them achieve the desired body weight. Therefore, use of CGM has the potential to enhance the early detection of dysglycemia (prediabetes and diabetes) and refine the current diagnostic criteria to help individualised interventions and prevent long-term complications.</p>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 4","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body Composition and Regional Adiposity in Adolescents With Type 1 Diabetes: Relation to Insulin Resistance, Glycaemic Control and Vascular Complications","authors":"Safinaz Adel Elhabashy,&nbsp;Bassma Abdelnasser Abdelhaleem,&nbsp;Sherihane Saieed Madkour,&nbsp;Christein Monir Kamal,&nbsp;Nouran Yousef Salah","doi":"10.1002/dmrr.70041","DOIUrl":"https://doi.org/10.1002/dmrr.70041","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Obesity is increasingly recognized among people with type 1 diabetes mellitus (T1DM). Little is known about the body composition of adolescents with T1DM and its metabolic outcomes. Hence, this study assessed the body composition of adolescents with T1DM and its relationship with glycaemic control, insulin resistance and vascular complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>One hundred twenty adolescents with T1DM were assessed for anthropometric measures, insulin therapy, bioelectrical impedance analysis (BIA), fasting lipids, glycated haemoglobin, with estimated glucose disposal rate (eGDR) calculation. Regional body fat quantification was performed via Magnetic resonance imaging (MRI) 3-T.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-three adolescents with T1DM were overweight (27.5%), and 8 were obese (6.6%). Adolescents with T1DM having insulin resistance were found to have significantly higher BMI <i>z</i> score, total body fat %, and visceral/subcutaneous fat % than those without insulin resistance (<i>p</i> &lt; 0.05). Moreover, adolescents with T1DM having microvascular complications showed significantly higher total fat % and visceral/subcutaneous fat % than those without microvascular complications (<i>p</i> &lt; 0.05). Visceral fat % and visceral/subcutaneous fat ratio were positively correlated with waist/hip ratio, eGDR and LDL level (<i>p</i> &lt; 0.05). Waist/hip ratio and eGDR were the most significant independent variables associated with visceral fat % and visceral/subcutaneous fat ratio among adolescents with T1DM using multivariate regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overweight and visceral adiposity are frequently encountered among the studied adolescents with T1DM. Visceral adiposity is associated with insulin resistance, hyperlipidaemia and microvascular complications among adolescents with T1DM independent of glycaemic control and insulin dosage.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 4","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143770254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Artificial Intelligence in the Diagnosis and Management of Metabolic Syndrome: A Comprehensive Review","authors":"Jingjing Liu,&nbsp;Zhangdaihong Liu,&nbsp;Chang Liu,&nbsp;Hong Sun,&nbsp;Xiaoguang Li,&nbsp;Yang Yang","doi":"10.1002/dmrr.70039","DOIUrl":"https://doi.org/10.1002/dmrr.70039","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Metabolic syndrome (MetS) is a progressive chronic pathophysiological state characterised by abdominal obesity, hypertension, hyperglycaemia, and dyslipidaemia. It is recognised as one of the major clinical syndromes affecting human health, with approximately one-quarter of the global population impacted. MetS increases the risk of developing cardiovascular diseases (CVDs), stroke, type 2 diabetes mellitus (T2DM), and diverse metabolic diseases. Early diagnosis of MetS could potentially reduce the prevalence of these diseases. However, care for the MetS population faces significant challenges due to (i) a lack of comprehensive understanding of the full spectrum of associated diseases, stemming from unclear pathophysiological mechanisms and (ii) frequent underdiagnosis or misdiagnosis of MetS in clinical settings due to inconsistent screening guidelines, limited medical resources, time constraints in clinical practice, and insufficient awareness and training. The increasing availability of healthcare and medical data presents opportunities to apply and innovate with artificial intelligence (AI) in addressing these challenges. This review aims to (i) summarise the spectrum of diseases associated with MetS and (ii) review the diverse AI models applied to MetS and metabolic syndrome-related diseases (MetSRD), where MetSRD collectively refers to diseases and conditions directly associated with MetS.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Our review consists of two phases. Initially, we conducted a literature review on MetS to narrow down the spectrum of MetSRD based on the strength of clinical evidence. We then used the terms ‘Metabolic Syndrome’ and ‘Machine Learning’ in combination with the identified MetSRD for further refinement. In total, we identified 52 related diseases in the first phase and 36 articles in the second phase.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We identified a total of 52 MetSRD after the first phase, with T2DM, CVDs, and cancer being the top three. Among the 36 articles obtained in the second phase, we observed the following: (i) The criteria for MetS were inconsistent across the studies. (ii) The primary purpose of AI applications was to identify risk factors for diseases, thereby improving predictions for MetS or MetSRD. Traditional machine learning models, such as Random Forest and Logistic Regression, were found to be the most effective. (iii) In addition to the MetS criteria, AI models explored other factors, including demographic and physiological variables, dietary influences, lipidomic and proteomic indicators, and more.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 ","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 4","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Benefits and Risks of Metabolic Surgery for Long-Term (5 Years) Weight Loss and Diabetes Remission in Overweight/Obese Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized Trials","authors":"Xiaoyu Zang,&nbsp;Tong Lin,&nbsp;Jing Ma,&nbsp;Ying Zhang,&nbsp;Boxun Zhang,&nbsp;Yishan Huang,&nbsp;Danni Zhou,&nbsp;Lu Ding,&nbsp;Lili Zhang,&nbsp;Linhua Zhao","doi":"10.1002/dmrr.70033","DOIUrl":"https://doi.org/10.1002/dmrr.70033","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;While there have been studies comparing the efficiency of several metabolic operations in overweight or obese individuals with type 2 diabetes mellitus (T2DM), there is currently no comprehensive evidence about the complete remission of diabetes and its long-term safety.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This comprehensive review and network meta-analysis encompassed searches of many databases including PubMed, Web of Science, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, ClinicalTrials.gov, and Google Scholar. The search was conducted from the beginning of these databases’ existence until 1 May 2024. The study selected randomized controlled trials (RCTs) with a 5-year follow-up period to compare the clinical benefits and evaluate the occurrence of side events. The network meta-analysis employed a random-effects model. The registration number for PROSPERO is CRD42023412536.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;There was a total of 16 RCTs that included 1059 patients. A total of 897 patients, representing 84.7% of the entire sample, successfully completed the 5-year follow-up. Seven metabolic procedures were conducted. All ensuing estimates are to the comparison with a non-surgical treatment (NST). The evidence strongly supports that One-anastomosis gastric bypass (OAGB) is the most effective surgical procedure for achieving long-term complete remission of diabetes (relative risk [RR] 10.28, 95% CI 1.87 to 56.40). Additionally, Biliopancreatic diversion (BPD) is the most effective procedure for achieving long-term partial remission of diabetes (RR 16.74, 95% CI 4.66 to 60.12). The study found that BPD was the most successful method for long-term weight loss, with a mean difference of −11.68 in BMI decrease (95% CI −15.06 to −8.31) and a mean difference of −32.01 in weight change (95% CI −43.27 to −20.74). The evidence supporting this conclusion is of moderate quality. Regarding the occurrence of adverse events and complications related to surgery, gastrointestinal, macrovascular, and microvascular issues are not as frequent in BPD compared with NST (relative risk 0.29, 95% confidence interval 0.06 to 1.37). On the other hand, OAGB may have a higher occurrence of these difficulties, second only to BPD (relative risk 0.08, 95% confidence interval 0.2 to 3.29). Based on the findings on effectiveness and safety, it has been determined that OAGB (One Anastomosis Gastric Bypass) is more effective in obtaining long-term complete remission of diabetes and in assuring overall safety in diabetes management. However, BPD is superior to OAGB in terms of partial remission, weight loss and safety in diabetes management, ranking secon","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 3","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Prediction Model for Predicting 10-year Incidence of Type 2 Diabetes in Japanese People; Panasonic Cohort Study 7","authors":"Chihiro Munekawa,&nbsp;Go Horiguchi,&nbsp;Akari Naito,&nbsp;Masahide Hamaguchi,&nbsp;Kazushiro Kurogi,&nbsp;Hiroaki Murata,&nbsp;Masato Ito,&nbsp;Akihiro Obora,&nbsp;Takao Kojima,&nbsp;Hiroshi Okada,&nbsp;Satoshi Teramukai,&nbsp;Michiaki Fukui","doi":"10.1002/dmrr.70040","DOIUrl":"https://doi.org/10.1002/dmrr.70040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In Japan, several prediction models and scoring systems for type 2 diabetes have been reported; however, none have high utility. We developed a new clinical prediction model for the onset of type 2 diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>The development dataset was obtained from 72,124 Japanese employees who participated in a health check-up programme conducted by Panasonic Corporation (Osaka, Japan), were aged 40 years or older, were diabetes-free at baseline, and followed-up for up to 10 years. The external validation dataset was obtained from 12,885 participants of the NAGALA (Gifu City, Gifu Prefecture Longitudinal Analysis) cohort. A prediction model was developed to predict the 10-year risk of developing diabetes using information from the health checkup programme. The developed model was internally validated, and externally validated using the NAGALA cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Using information on age, sex, body mass index, systolic blood pressure, log-triglycerides, high-density lipoprotein, log-alanine aminotransferase, fasting plasma glucose, weight gain, and smoking status obtained from a health checkup programme, we developed a novel, highly sensitive, and specific model for predicting the 10-year risk of developing diabetes. The prediction model showed excellent performance, with an optimism-corrected c-index of 0.877 and a c-index of 0.882 in the external validation cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We developed a noninvasive diabetes risk-prediction model for the Japanese population and confirmed its utility for identifying individuals at high risk of type 2 diabetes over time.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 3","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging Pubertal Changes and Endotype Based Therapy in Type 1 Diabetes","authors":"M. A. Roma-Wilson,&nbsp;R. Buzzetti,&nbsp;S. Zampetti","doi":"10.1002/dmrr.70038","DOIUrl":"https://doi.org/10.1002/dmrr.70038","url":null,"abstract":"<p>The intersection of puberty with the onset of type 1 diabetes (T1D) presents unique pathogenic, clinical and psychosocial challenges, necessitating nuanced management strategies that account for developmental changes and the disease's heterogeneity. The distinction between pre-pubertal (T1DE1) and pubertal (T1DE2) T1D onset underscores the need for tailored approaches to monitoring and therapy during this critical period. Patients, with severe <i>β</i>-cell loss and heightened metabolic demands during puberty, require more intensive glycaemic management and screening for growth delays and pubertal disruptions. Meanwhile, pubertal T1D patients, though benefiting from relatively preserved <i>β</i>-cell function, still face heightened risks of insulin resistance and comorbidities such as obesity that demand vigilant monitoring and individualised interventions. Key actionable recommendations include implementing systematic screening protocols for growth impairment, menstrual abnormalities, and early markers of microvascular complications. Advanced technologies such as continuous glucose monitors and automated insulin delivery systems to reduce the glycaemic burden before and during puberty warrant robust investigation. The integration of behavioural interventions that enhance self-regulation and family-centred care into routine diabetes management can yield valuable insights into improving adherence and glycaemic control.</p>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 3","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of an Advanced Hybrid Closed Loop System During Marathon Running: Case Examples and Clinical Implications","authors":"María T. Onetto,&nbsp;Denise Montt-Blanchard,&nbsp;Cari Berget,&nbsp;Kristel Strodhoff,&nbsp;Bruno Grassi","doi":"10.1002/dmrr.70034","DOIUrl":"https://doi.org/10.1002/dmrr.70034","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and aims</h3>\u0000 \u0000 <p>Maintaining glucose levels in the target range during aerobic training and athletic competition is especially difficult. The use of Automated Insulin Delivery (AID) technology is increasing, but exercise continues to be a challenge for persons with type 1 diabetes (T1D). In this case report series, we present 3 cases (C1, C2 and C3) of persons with T1D who used the MiniMed 780G during marathon races. We describe the strategies they used before, during and after the race to manage their glycaemia as well as the results of these strategies on their glycaemic control during the race.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Medtronic CareLink platform was employed to remotely access insulin pump settings and glycaemic outcomes. Race parameters were obtained from sport watches. Supplemental data were obtained through interviews.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Carelink data for Cases 1, 2, and 3 before the race were downloaded: Time in range (TIR) 70–180 mg/dL 89%, 76%, 82%; time above range (TAR) &gt; 180 mg/dL, 9%, 20%, 16%; time below range (TBR) &lt; 70 mg/dL, 1%, 4%, 1%, respectively. The breakfast insulin reduction percentages were −25%, 0%, and 0% for C1, C2, and C3, respectively. In all three cases, insulin dose reduction was applied to the pre-race snack at percentages of −50%, −100% and −83%. The consumption of carbohydrates during the race was 0.39 g/kg/hour, 0.42 g/kg/hour, and 0.5 g/kg/hour, respectively. The total amount of carbohydrates consumed was 101 g, 120 g, and 115 g, respectively. Throughout the race, a temporary target was used for all cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These cases provide insights for healthcare professionals who assist athletes with T1D using AID systems during prolonged physical activities. Highlighting the significance of specialised education, planning, and personalised approaches.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 3","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143513808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}